World­wide, tuber­cu­lo­sis claims about 1.5 mil­lion vic­tims per year. It is one of the most dan­ger­ous dis­eases caused by bac­te­ria. The increas­ing spread of multi-resis­tant strains of the pathogen is par­tic­u­larly wor­ry­ing. A group of researchers and entre­pre­neurs is cur­rently devel­op­ing an antibi­otic with pub­lic fund­ing that is also effec­tive against resis­tant strains.
A promis­ing active sub­stance against tuber­cu­lo­sis is now about to undergo clin­i­cal tri­als. The active ingre­di­ent is being man­u­fac­tured by HAPILA GmbH, a port­fo­lio com­pany of bm|t.
https://youtu.be/

www.infectcontrol.de/de/anzeigen/